291 related articles for article (PubMed ID: 16860997)
1. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
2. Drug insight: advances in renal cell carcinoma and the role of targeted therapies.
Larkin JM; Chowdhury S; Gore ME
Nat Clin Pract Oncol; 2007 Aug; 4(8):470-9. PubMed ID: 17657252
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
4. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
5. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
6. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in the treatment of metastatic renal cell cancer.
Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
12. Improving outcomes in patients with advanced renal cell carcinoma.
Sosman JA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
14. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Paule B; Brion N
Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
[TBL] [Abstract][Full Text] [Related]
17. Combination systemic therapy for advanced renal cell carcinoma.
Miller RE; Larkin JM
Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
[TBL] [Abstract][Full Text] [Related]
18. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
19. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
20. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
